Yes, lenvatinib can shrink tumors in certain types of cancer, particularly hepatocellular carcinoma (HCC) (liver cancer), renal cell carcinoma (RCC) (kidney cancer) and differentiated thyroid cancer that is resistant to radioactive iodine treatment and Lenvatinib Cost Philippines.
How lenvatinib works:
Lenvatinib is a multi-kinase inhibitor that works by targeting and inhibiting several receptors involved in tumor growth and blood vessel formation (angiogenesis), including:
VEGFR (vascular endothelial growth factor receptor)
FGFR (fibroblast growth factor receptor)
PDGFR (platelet-derived growth factor receptor)
KIT
RET
By blocking these pathways, lenvatinib slows tumor growth and may also shrink them. Specifically, lenvatinib interferes with the tumor's ability to develop a blood supply, which is essential for its growth and survival.
Tumor shrinkage in specific cancers:
Hepatocellular carcinoma (HCC):
In patients with advanced liver cancer, lenvatinib has shown the ability to shrink tumors and slow disease progression. It is often used when surgery or other treatments are not options, and clinical studies have demonstrated that lenvatinib can cause significant tumor shrinkage in some patients.
Renal cell carcinoma (RCC):
Lenvatinib is used with everolimus to treat advanced RCC, and it has been shown to shrink tumors or stabilize disease progression. In clinical trials, patients treated with lenvatinib have improved progression-free survival (PFS), and tumor shrinkage is often observed.
Differentiated thyroid cancer:
Lenvatinib is approved for differentiated thyroid cancer that no longer responds to radioactive iodine treatment. In this context, it may cause tumour shrinkage in some patients, leading to disease control and improvement of symptoms.
Clinical evidence:
In clinical studies, lenvatinib has been shown to reduce tumour size in various cancers, particularly in HCC and RCC, where a proportion of patients showed significant tumour shrinkage. Tumour shrinkage can be assessed through imaging techniques such as CT scan or MRI, which help doctors evaluate how well treatment is working.
Summary:
Yes, lenvatinib can shrink tumours in some cancers, particularly hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid cancer. It works by inhibiting angiogenesis (blood vessel formation) and blocking multiple growth pathways, ultimately slowing tumor growth and potentially reducing tumor size. The effectiveness of lenvatinib varies from patient to patient, with some experiencing significant tumor shrinkage while others may experience stable disease. Regular monitoring is necessary to assess the effectiveness of the treatment and Lenvatinib Price Malaysia.
